ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

Gerber DE; Minna JD

首页> 外文期刊>Cancer Cell >ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

【24h】

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

机译：非小细胞肺癌的ALK抑制：从发现到治疗的记录时间。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

It was only 3 years ago that an acquired translocation of EML4 with ALK leading to the expression of an EML4-ALK oncoprotein in non-small cell lung cancer (NSCLC) was reported. Tumor cells expressing EML4-ALK are "addicted" to its continued function. Now, crizotinib, an oral ALK inhibitor, is demonstrated to provide dramatic clinical benefit with little toxicity in patients having such advanced NSCLC, and a mechanism of clinical resistance to crizotinib is identified. Such therapy "targeted" at oncogenic proteins provides "personalized" medicine and prompts genome-wide mutation analysis of human tumors to find other therapeutic targets.

机译：仅在3年前，据报道，EML4与ALK易位，导致非小细胞肺癌（NSCLC）中EML4-ALK癌蛋白的表达。表达EML4-ALK的肿瘤细胞被“认为”其持续功能。现在，已证明口服ALK抑制剂克唑替尼在具有这种晚期NSCLC的患者中提供了巨大的临床益处，并且几乎没有毒性，并且鉴定了对克唑替尼的临床耐药性机制。这种“靶向”致癌蛋白的疗法提供了“个性化”药物，并促进了人类肿瘤全基因组突变分析，从而找到了其他治疗靶标。

著录项

来源
《Cancer Cell》 |2010年第6期|共4页
作者
Gerber DE; Minna JD;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. [J] . Gerber DE, Minna JD Cancer Cell . 2010,第6期

机译：非小细胞肺癌的ALK抑制：从发现到治疗的记录时间。
2. Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer [J] . N. Shrestha, M. Nimick, P. Dass, Scientific reports. . 2019,第1期

机译：通过在ALK阳性非小细胞肺癌中对ALK和MEK进行双重抑制细胞生长的机制
3. 155 EML4-ALK signaling is required for the maintenance of neoplastic phenotype of non-small cell lung cancer cells: novel strategy for lung cancer tailored therapies [J] . C. Voena, E. Panizza, E. Pellegrino, European Journal of Cancer Supplements . 2010,第7期

机译：155 EML4-ALK信号传导对于维持非小细胞肺癌细胞的肿瘤表型是必需的：针对肺癌的新疗法
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. Oral Combination Therapy Dosage Forms for Improved Response in Resistant Non-Small Cell Lung Cancers [D] . Nottingham, Ebony. 2020

机译：口腔组合治疗剂型改善抗性非小细胞肺癌的响应
6. ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time [O] . David E. Gerber, John D. Minna -1

机译：aLK抑制对非小细胞肺癌：从发现到治疗的记录时间
7. ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time [O] . Gerber David E., Minna John D. 2010

机译：ALK对非小细胞肺癌的抑制作用：从发现到治疗的记录时间

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

摘要

著录项

相似文献

相关主题

期刊订阅